The p53 tumor suppressor gene: From molecular biology to clinical investigation

Annals of the New York Academy of Sciences

Volumn 910, Issue , 2000, Pages 121-139

  Soussi, Thierry ^a,b  

^a INSTITUT CURIE   (France)

^b Lab de Genotoxicologie des Tumeurs   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MUTANT PROTEIN; PROTEIN P53;

APOPTOSIS; BRAIN CANCER; BREAST CANCER; CANCER; CELL CYCLE; COLON CANCER; CONFERENCE PAPER; DNA REPAIR; DRUG SENSITIVITY; ESOPHAGUS CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; POINT MUTATION; PROTEIN STABILITY; STOMACH CANCER; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

EID: 0033931447     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06705.x     Document Type: Conference Paper

References (107)

1. 1. NIGRO, J.M., S.J. BAKER, A.C. PREISINGER et al. 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708.
2. 2. TAKAHASHI, T., M.M. NAU, I. CHIBA et al. 1989. p53 - a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494.
3. 3. BÉROUD, C. & T. SOUSSI. 1998. p53 gene mutation: software and database. Nucleic Acids Res. 26: 200-204.
4. 4. GREENBLATT, M.S., W.P. BENNETT, M. HOLLSTEIN & C.C. HARRIS. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.
5. 5. SOUSSI, T., K. DEHOUCHE & C. BÉROUD. 2000. Analysis of p53 mutation in human cancer: the link between epidemiology and carcinogenesis. Hum. Mut. In press.
6. 6. LEVINE, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
7. 7. MALKIN, D., F.P. LI, L.C. STRONG et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238.
8. 8. KASTAN, M.B., O. ONYEKWERE, D. SIDRANSKY, B. VOGELSTEIN & R.W. CRAIG. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
9. 9. KUERBITZ, S.J., B.S. PLUNKETT, W.V. WALSH, M.B. KASTAN. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89: 7491-7495.
10. 10. YONISH-ROUACH, E., D. RESNITZKY, J. LOTEM, L. SACHS, A. KIMCHI & M. OREN. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347.
11. 11. FRITSCHE, M., C. HAESSLER & G. BRANDNER. 1993. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318.
12. 12. GIACCIA, A.J. & M.B. KASTAN. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12: 2973-2983.
13. 13. LANE, D. 1992. p53, guardian of the genome. Nature 358: 15-16.
14. 14. BATES, S., A.C. PHILLIPS, P.A. CLARK et al. 1998. p14(ARF) links the tumour suppressors RB and p53. Nature 395: 124-125.
15. 15. GRAEBER, T.G., C. OSMANIAN, T. JACKS et al. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91.
16. 16. LINKE, S.P., K.C. CLARKIN, A. DILEONARDO, A. TSOU & G.M. WAHL. 1996. A reversible, p53-dependent G(0)/G(1) cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Gene Dev. 10: 934-947.
17. 17. KAELIN, W.G. 1999. The emerging p53 gene family. J. Nat. Cancer Inst. 91: 594-598.
18. 18. AGAMI, R., G. BLANDINO, M. OREN & Y. SHAUL. 1999. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806-809.
19. 19. JOST, C.A., M.C. MARIN & W.G. KAELIN. 1999. p73 is regulated by tyrosine kinase c-Ab1 in the apoptotic response to DNA damage. Nature 399: 814-817.
20. 20. YUAN, Z.M., H. SHIOYA, T. ISHIKO et al. 1999. Interaction of c-Ab1 and p73 alpha and their collaboration to induce apoptosis. Nature 399: 809-813.
21. 21. LOWE, S.W., H.E. RULEY, T. JACKS & D.E. HOUSMAN. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
22. 22. FAN, S.J., W.S. EL-DEIRY, I. BAE et al. 1994. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54: 5824-5830.
23. 23. ELIOPOULOS, A.G., D.J. KERR, J. HEROD et al. 1995. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 11: 1217-1228.
24. 24. XIA, F., X. WANG, Y.H. WANG et al. 1995. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res. 55: 12-15.
25. 25. FAN, S.J., M.L. SMITH, D.J. RIVET et al. 1995. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55: 1649-1654.
26. 26. O'CONNOR, P.M., J. JACKMAN, D. JONDLE, K. BHATIA, I. MAGRATH & K.W. KOHN. 1993. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitts lymphoma cell lines. Cancer Res. 53: 4776-4780.
27. 27. WU, G.S. & W.S. EL-DEIRY. 1996. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin. Cancer Res. 2: 623-633.
28. 28. WU, G.S. & W.S. EL-DEIRY. 1996. p53 and chemosensitivity. Nature Med. 2: 255-256.
29. 29. MONZO, M., R. ROSELL, J.J. SANCHEZ et al. 1999. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutation. J. Clin. Oncol. 17: 1786-1793.
30. 30. FUJIWARA, T., E.A. GRIMM, T. MUKHOPADHYAY, W.W. ZHANG, L.B. OWENSCHAUB & J.A. ROTH. 1994. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54: 2287-2291.
31. 31. SPITZ, F.R., D. NGUYEN, J.M. SKIBBER, R.E. MEYN, R.J. CRISTIANO & J.A. ROTH. 1996. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res. 2: 1665-1671.
32. 32. YANG, B., J.R. ESHLEMAN, N.A. BERGER & S.D. MARKOWITZ. 1996. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin. Cancer Res. 2: 1649-1657.
33. 33. BLAGOSKLONNY, M.V. & W.S. EL-DEIRY. 1996. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int. J. Cancer 67: 386-392.
34. 34. SOUSSI, T., Y. LEGROS, R. LUBIN, K. ORY & B. SCHLICHTHOLZ. 1994. Multifactorial analysis of p53 alteration in human cancer - a review. Int. J. Cancer 57: 1-9.
35. 35. AHRENDT, S.A., S. HALACHMI, J.T. CHOW et al. 1999. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc. Natl. Acad. Sci. USA 96: 7382-7387.
36. 36. DOWELL, S.P., P.O.G. WILSON, N.W. DERIAS, D.P. LANE & P.A. HALL. 1994. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 54: 2914-2918.
37. 37. TOP, B., W.J. MOOI, S.G. KLAVER et al. 1995. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int. J. Cancer 64: 83-91.
38. 38. CASEY, G., M.E. LOPEZ, J.C. RAMOS et al. 1996. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13: 1971-1981.
39. 39. TENAUD, C., A. NEGOESCU, F. LABATMOLEUR, Y. LEGROS, T. SOUSSI & E. BRAMBILLA. 1994. Methods in pathology - p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas. Mod. Pathol. 7: 853-859.
40. 40. LEGROS, Y., C. LAFON & T. SOUSSI. 1994. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene 9: 2071-2076.
41. 41. VOJTESEK, B., J. BARTEK, C.A. MIDGLEY & D.P. LANE. 1992. An immunochemical analysis of the human nuclear phosphoprotein-p53 - new monoclonal antibodies and epitope mapping using recombinant-p53. J. Immunol. Methods 151: 237-244.
42. 42. CRAWFORD, L.V., D.C. PIM & R.D. BULBROOK. 1982. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer 30: 403-408.
43. 43. CARON DE FROMENTEL, C., F. MAY-LEVIN, H. MOURIESSE, J. LEMERLE, K. CHANDRASEKARAN & P. MAY. 1987. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer 39: 185-189.
44. 44. SOUSSI, T. 1996. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol. Today 17: 354-356.
45. 45. HOUBIERS, J.G.A., S.H. VANDERBURG, L.M.G. VANDEWATERING et al. 1995. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br. J. Cancer 72: 637-641.
46. 46. ANGELOPOULOU, K., M. STRATIS & E.P. DIAMANDIS. 1997. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int. J. Cancer 70: 46-51.
47. 47. HAMMEL, P., B. BOISSIER, M.T. CHAUMETTE et al. 1997. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40: 356-361.
48. 48. SHIBATA, Y., H. KOTANOGI, H. ANDOH, K. KOYAMA, H. ITOH & S. KUDO. 1996. Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Dis. Colon Rectum 39: 1269-1274.
49. 49. STHOEGER, Z., E. EVRON, S. GOLAND et al. 1997. Anti-p53 antibodies in colon cancer patients. Ann. N.Y. Acad. Sci. 815: 496-498.
50. 50. POLGE, A., J.F. BOURGAUX, E. BANCEL et al. 1998. p53 and follow-up of colorectal adenocarcinomas. Dig. Dis. Sci. 43: 1434-1442.
51. 51. KRESSNER, U., B. GLIMELIUS, R. BERGSTROM, L. PAHLMAN, A. LARSSON & G. LINDMARK. 1998. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br. J. Cancer 77: 1848-1851.
52. 52. ZALCMAN, G., B. SCHLICHTHOLZ, J. TRÉDANIEL et al. 1998. Monitoring of p53 auto antibodies in lung cancer during therapy: relationship to response to treatment. Clin. Cancer Res. 4: 1359-1366.
53. 53. LUBIN, R., G. ZALCMAN, L. BOUCHET et al. 1995. Serum p53 antibodies as early markers of lung cancer. Nature Med. 1: 701-702.
54. 54. TRIVERS, G.E., V.M.G. DE BENEDETTI, H.L. CAWLEY et al. 1996. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin. Cancer Res. 2: 1767-1775.
55. 55. CAWLEY, H.M., S.J. MELTZER, V.M. DE BENEDETTI et al. 1998. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology 115: 19-27.
56. 56. ISHIOKA, C., T. FREBOURG, Y. YAN et al. 1993. Screening patients for heterozygotous p53 mutations using a functional assay in yeast. Nature Genet. 5: 124-129.
57. 57. FLAMAN, J.M., T. FREBOURG, V. MOREAU et al. 1995. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA 92: 3963-3967.
58. 58. FUJIMOTO, H., J. SASAKI, M. MATSUMOTO et al. 1998. Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma. Jpn. J. Cancer Res. 89: 696-702.
59. 59. YUEN, S.T., L.P. CHUNG, S.Y. LEUNG et al. 1997. Colorectal carcinoma in Hong Kong: epidemiology and genetic mutations. Br. J. Cancer 76: 1610-1616.
60. 60. SOUSSI, T. 1996. The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Mol. Med. Today 2: 32-37.
61. 61. SUZUKI, H., T. TAKAHASHI, T. KUROISHI et al. 1992. p53 mutations in non-small-cell lung cancer in Japan - association between mutations and smoking. Cancer Res. 52: 734-736.
62. 62. TAKAGI, Y., H. OSADA, T. KUROISHI et al. 1998. p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br. J. Cancer 77: 1568-1572.
63. 63. DENISSENKO, M.F., A. PAO, M.S. TANG & G.P. PFEIFER. 1996. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274: 430-432.
64. 64. CARON DE FROMENTEL, C. & T. SOUSSI. 1992. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chrom. Cancer 4: 1-15.
65. 65. HSU, I.C., R.A. METCALF, T. SUN, J.A. WELSH, N.J. WANG & C.C. HARRIS. 1991. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428.
66. 66. BRESSAC, B., M. KEW, J. WANDS & M. OZTURK. 1991. Selective G-mutation to T-mutation of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350: 429-431.
67. 67. OZTURK, M. et al. 1991. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338: 1356-1359.
68. 68. AGUILAR, F., C.C. HARRIS, T. SUN, M. HOLLSTEIN & P. CERUTTI. 1994. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264: 1317-1319.
69. 69. PUISIEUX, A., S. LIM, J. GROOPMAN & M. OZTURK. 1991. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 51: 6185-6189.
70. 70. BRASH, D.E., J.A. RUDOLPH, J.A. SIMON et al. 1991. A role for sunlight in skin cancer - UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 88: 10124-10128.
71. 71. ZIEGLER, A., A.S. JONASON, D.J. LEFFELL et al. 1994. Sunburn and p53 in the onset of skin cancer. Nature 372: 773-776.
72. 72. DUMAZ, N., A. STARY, T. SOUSSI, L. DAYAGROSJEAN & A. SARASIN. 1994. Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene? Mutat. Res. 307: 375-386.
73. 73. KINZLER, K.W. & B. VOGELSTEIN. 1996. Lessons from hereditary colorectal cancer. Cell 87: 159-170.
74. 74. SPARKS, A.B., P.J. MORIN, B. VOGELSTEIN & K.W. KINZLER. 1998. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58: 1130-1134.
75. 75. POTTER, J.D. 1999. Colorectal cancer: molecules and populations. J. Natl. Cancer Inst. 91: 916-932.
76. 76. OLSCHWANG, S., R. HAMELIN, P. LAURENT-PUIG et al. 1997. Alternative genetic pathways in colorectal carcinogenesis. Proc. Natl. Acad. Sci. USA 94: 12122-12127.
77. 77. NORDGREN, H., A. LINDGREN & J. BERGH. 1996. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry -response. J. Natl. Cancer Inst. 88: 1500.
78. 78. TOMIZAWA, Y., T. KOHNO, T. FUJITA et al. 1999. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 18: 1007-1014.
79. 79. FISHER, C.J., C.E. GILLETT, B. VOJTESEK, D.M. BARNES & R.R. MILLIS. 1994. Problems with p53 immunohistochemical staining - the effect of fixation and variation in the methods of evaluation. Br. J. Cancer 69: 26-31.
80. 80. VOJTESEK, B., C.J. FISHER, D.M. BARNES & D.P. LANE. 1993. Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br. J. Cancer 67: 1254-1258.
81. 81. JACOBS, T.W., J.E. PRIOLEAU, I.E. STILLMAN & S.J. SCHNITT. 1996. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. Natl. Cancer Inst. 88: 1054-1059.
82. 82. WYNFORD-THOMAS, D. 1992. p53 in tumour pathology - can we trust immunocytochemistry. J. Pathol. 166: 329-330.
83. 83. WYNFORD-THOMAS, D. 1995. Assessment of p53 overexpression by non-immunohistochemical methods - reply. J. Pathol. 175: 94-95.
84. 84. HALL, P.A. & D.P. LANE. 1994. P53 in tumour pathology - can we trust immunohistochemistry - revisited. J. Pathol. 172: 1-4.
85. 85. DIAMANDIS, E.P. & M.A. LEVESQUE. 1995. Assessment of p53 overexpression by non-immunohistochemical methods. J. Pathol. 175: 93-94.
86. 86. HAMELIN, R., P. LAURENT-PUIG, S. Olschwang et al. 1994. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106: 42-48.
87. 87. GOH, H.S., C.S. CHAN, K. KHINE & D.R. SMITH. 1994. p53 and behaviour of colorectal cancer. Lancet 344: 233-234.
88. 88. SMITH, D.R., C.Y. JI & H.S. GOH. 1996. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br. J. Cancer 74: 216-223.
89. 89. PRICOLO, V.E., S.D. FINKELSTEIN, T.T. WU et al. 1996. Prognostic value of TP53 and k-ras-2 mutational analysis in stage III carcinoma of the colon. Am. J. Surg. 171: 41-46.
90. 90. DIX, B.R., P. ROBBINS, R. SOONG et al. 1994. The common molecular genetic alterations in dukes' b and c colorectal carcinomas are not short-term prognostic indicators of survival. Int. J. Cancer 59: 747-751.
91. 91. REMVIKOS, Y., O. TOMINAGA, P. HAMMEL et al. 1992. Increased p53 protein content of colorectal tumours correlates with poor survival. Br. J. Cancer 66: 758-764.
92. 92. SUN, X.F., J.M. CARSTENSEN, H. ZHANG et al. 1992. Prognostic significance of cytoplasmic-p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369-1373.
93. 93. AUVINEN, A., J. ISOLA, T. VISAKORPI, T. KOIVULA, S. VIRTANEN & M. HAKAMA. 1994. Overexpression of p53 and long-term survival in colon carcinoma. Br. J. Cancer 70: 293-296.
94. 94. BOSARI, S., G. VIALE, P. BOSSI et al. 1994. Cytoplasmic accumulation of p53 protein -an independent prognostic indicator in colorectal adenocarcinomas. J. Natl. Cancer Inst. 86: 681-687.
95. 95. BELL, S.M., N. SCOTT, D. CROSS et al. 1993. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104: 57-64.
96. 96. MORRIN, M., M. KELLY, N. BARRETT & P. DELANEY. 1994. Mutations of ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 35: 1627-1631.
97. 97. MULDER, J.W.R., I.O. BAAS, M.M. POLAK, S.N. GOODMAN & G.J.A. OFFERHAUS. 1995. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br. J. Cancer 71: 1257-1262.
98. 98. KRESSNER, U., G. LINDMARK, B. GERDIN, L. PAHLMAN & B. GLIMELIUS. 1996. Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res. 16: 951-957.
99. 99. POLLER, D.N., K.J. BAXTER & N.A. SHEPHERD. 1997. p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br. J. Cancer 75: 87-93.
100. 100. FRIEDLANDER, P., Y. HAUPT, C. PRIVES, M. OREN. 1996. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16: 4961-4971.
101. 101. FRIEDLANDER, P., Y. LEGROS, T. SOUSSI & C. PRIVES. 1996. Regulation of mutant p53 temperature-sensitive DNA binding. J. Biol. Chem. 271: 25468-25478.
102. 102. FORRESTER, K., S.E. LUPOLD, V.L. OTT et al. 1995. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10: 2103-2111.
103. 103. LUDWIG, R.L., S. BATES & K.H. VOUSDEN. 1996. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16: 4952-4960.
104. 104. RYAN, K.M. & K.H. VOLSDEN. 1998. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol. Cell. Biol. 18: 3692-3698.
105. 105. GOH, H.S., J. YAO & D.R. SMITH. 1995. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 55: 5217-5221.
106. 106. BORRESEN DALE, A.L., R.A. LOTHE, G.I. MELING, P. HAINAUT, T.O. ROGNUM & E. SKOVLUND. 1998. Tp53 and long-term prognosis in colorectal cancer - mutations in the 13 zinc-binding domain predict poor survival. Clin. Cancer Res. 4: 203-210.
107. 107. KRESSNER, U., M. INGANAS, S. BYDING et al. 1999. Prognostic value of p53 genetic changes in colorectal cancer. J. Clin. Oncol. 17: 593-599.